about
A positive role of mammalian Tip41-like protein, TIPRL, in the amino-acid dependent mTORC1-signaling pathway through interaction with PP2AMolecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advancesHepatocellular carcinoma and non-alcoholic steatohepatitis: The state of playHepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesUnique genomic profile of fibrolamellar hepatocellular carcinoma.Everolimus and Malignancy after Solid Organ Transplantation: A Clinical UpdateKnocking down disease: a progress report on siRNA therapeuticsSystematic review: Preventive and therapeutic applications of metformin in liver diseaseMetformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cellsHepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.Erzhi Pill® Repairs Experimental Liver Injury via TSC/mTOR Signaling Pathway Inhibiting Excessive Apoptosis.Chemopreventive strategies in hepatocellular carcinomaLiver cancer: Approaching a personalized care.N-Hydroxyphthalimide exhibits antitumor activity by suppressing mTOR signaling pathway in BT-20 and LoVo cells.Persistent effect of mTOR inhibition on preneoplastic foci progression and gene expression in a rat model of hepatocellular carcinoma.Synergistic antitumor activity of the combination of salubrinal and rapamycin against human cholangiocarcinoma cells.Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4.Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology.K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.TIP30 regulates lipid metabolism in hepatocellular carcinoma by regulating SREBP1 through the Akt/mTOR signaling pathway.CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis.mTORC2 controls cancer cell survival by modulating gluconeogenesis.Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition.Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development.Hepatocellular cancer risk in diabetes: not all diabetics are the same.A case of liver hemangioma with markedly reduced tumor size after metformin treatment: a case report.MIR21 drives resistance to Heat Shock Protein 90 inhibition in cholangiocarcinoma.Simvastatin and metformin inhibit cell growth in hepatitis C virus infected cells via mTOR increasing PTEN and autophagy.TRIM31 is upregulated in hepatocellular carcinoma and promotes disease progression by inducing ubiquitination of TSC1-TSC2 complex.Targeting autophagy in chemotherapy-resistant of hepatocellular carcinoma.miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways.Butein suppresses hepatocellular carcinoma growth via modulating Aurora B kinase activity
P2860
Q24312822-1C473F1F-B206-4208-97F2-98C5259C3C09Q26745338-1158D4AA-F038-4102-A8A9-523945DEE71BQ26764911-87A2DDD3-F524-48A3-B8E4-D3E64F69455DQ26772317-EEE3158B-7C38-4B96-AA89-C0B1E44248A2Q27853116-C4820AD0-862B-4C19-A7B7-3838CAF1E6C5Q28067598-99D5806C-D658-409C-8A00-D391A5B511ADQ28082939-79D79E9E-7286-45A9-B710-174CBFF28A22Q28085535-9B542622-0E29-4AE6-A3D0-CE10C8D94379Q28534922-01E2F0E6-2D0E-4957-BF65-D1898097BF66Q30234574-A3B60F54-C9EE-4EAC-B6D5-92E839E67685Q33415304-C93CEC1A-6BD3-484C-AEE7-790FDC68BBE5Q33790613-6BE454AA-B359-41BE-8BCF-EC0C676DCD14Q35101365-E675CE4C-E934-4A8B-9B31-9E0DBB4C8015Q35903794-3069C2E1-B4A6-4C97-A90F-FA57748D1B46Q36651651-1CECC47C-7517-481B-B04C-CB6A7D454F3BQ37220518-4397DF83-C2ED-4445-BD16-EA58DB42F07FQ37709171-54B4304C-3F2B-4973-B4DD-414EB3C846D0Q37718325-CCCDEEA0-E5F0-43A9-BE2A-CC1235CF9BDFQ38174585-33730997-15FC-48F0-ADF4-0870A92C1939Q38540375-41DAEE9E-75F5-4AD4-AA4E-0ABB0004C651Q38678966-7F60EA43-DD5B-4782-AD43-23BE231AD966Q38730344-E34C72E6-E35B-467A-ACF4-5283CBAF63D9Q38732561-42CA87E9-8A4C-47FF-802C-D87B55B5A5BEQ39463791-71E31FDE-37CB-4EDA-A162-F4B9B9E6F4C5Q42718504-D62B4727-D812-4B7C-B884-2CD51689AD0EQ43088347-592350DD-701D-4153-8582-ED5F1AB0E24AQ43552414-BEAEE1F8-090B-4405-890D-2064F10134A6Q47249592-336B2705-D004-48DC-85DE-8202605B5394Q47429093-AB3FAAC6-C654-4EB9-B814-32A612572524Q47547628-1DB89C17-8722-46B7-85B7-AB424561AAD2Q47716626-33282BE3-E635-4D42-A764-D8C8FD6EDC92Q53696566-90D11608-32A4-4B43-86B9-0099A39CE52DQ54963896-0E787BA8-F051-401F-B36B-C07DF371FCE2Q55035102-4D80D56E-1179-4B53-8E0E-8AD32581FC35Q58758540-16D4B745-0419-470F-8379-4B98725E53E1
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The mTOR pathway in hepatic malignancies.
@en
type
label
The mTOR pathway in hepatic malignancies.
@en
prefLabel
The mTOR pathway in hepatic malignancies.
@en
P2860
P356
P1433
P1476
The mTOR pathway in hepatic malignancies.
@en
P2093
Mamatha Bhat
P2860
P304
P356
10.1002/HEP.26323
P407
P577
2013-04-17T00:00:00Z